Citations

Clear

125 citation(s) found for "Tyson, MD".

Real‐World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy
Kumar, Nitish , Pace, Tyson, Gomes, Pedro Lança , Marino, Michael J. , Miglani, Amar , Lal, Devyani , Kumar, Nitish , Lal, Devyani , Lança Gomes, Pedro

Mayo Clinic

International Forum of Allergy & Rhinology | November 21, 2025 | Volume: 16 | Issue: 1 | Pages: 99-101

10.1002/alr.70072 | PMID 41269030 Get It

Key Points Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.
Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy
Fazili, Adnan , Jazayeri, Seyed Behzad , Wen, Lexiaochuan , Durant, Adri , Prunty, Megan , Tyson, Mark D. , Grass, G. Daniel , Xu, Hongzhi, Gilbert, Scott M. , Sexton, Wade J. , Zemp, Logan , Pessoa, Rodrigo Rodrigues, Poch, Michael , Durant, Adri M , Li, Roger , Rose, Kyle , Guske, Christopher W. , Bukavina, Laura , Spiess, Philippe E. , Lerner, Seth P. , Li, Roger

Mayo Clinic

BJU International | September 11, 2025 | Volume: 137 | Issue: 1 | Pages: 181-188

10.1111/bju.16895 | PMID 40932312 Get It

Objectives To compare survival and oncological outcomes of cisplatin‐ineligible patients (Cis‐I) and cisplatin‐eligible (Cis‐E) patients with muscle‐invasive bladder cancer (MIBC) undergoing immediate radical cystectomy (IRC), as IRC is currently considered the standard‐of‐care for Cis‐I patients with MIBC. Patients and Methods Data from patients with clinical (c)T2–4cN0–1M0 MIBC undergoing IRC, between 2006 and 2021, were retrospectively analysed from four tertiary care centres in the United States. Overall, recurrence‐free and event‐free survival were described using the Kaplan–Meier method and tested using the log‐rank test. For context, we compared survival outcomes against those in Cis‐E patients with MIBC undergoing IRC from the Southwest Oncology Group (SWOG)‐8710 trial. Results Overall, 379 Cis‐I and 125 Cis‐E patients with cT2–4cN0–1M0 MIBC who underwent IRC were included. Cis‐I patients included 44.8% cT3/4 vs 60% cT3/4 in the Cis‐E group. Overall, 83.3% of Cis‐I and 79.2% of Cis‐E patients died during follow‐up. The median event‐free and overall survival were 12.1 and 14.5 months for the Cis‐I group and 28.8 and 60.1 months for the Cis‐E group ( P < 0.001). [Correction added on 10 October 2025, after first online publication: The preceding sentence has been revised in this version.] Limitations include retrospective comparison of contemporary multi‐institutional data with that of a randomised control trial. Conclusions The Cis‐I patients with MIBC undergoing IRC fared poorly, with a median overall survival of 14.5 (95% confidence interval 11.1–17.9) months, mostly due to non‐cancer‐related deaths. These results provide a benchmark for clinical trials exploring novel agents or alternative chemotherapy regimens in Cis‐I patients with MIBC.
Outcomes of Reinduction With Nadofaragene Firadenovec
Schmidt, Bogdana, Horns, Joshua J. , Tyson, Mark D. , Linehan, Jennifer , Dickstein, Rian J., Daneshmand, Siamak , Agarwal, Piyush Kumar , Narayan, Vikram M. , Luckenbaugh, Amy N. , Lotan, Yair

Mayo Clinic

Journal of Urology | August 25, 2025 | Volume: 214 | Issue: 5 | Pages: 472-473

10.1097/ju.0000000000004697 | PMID 40852908 Get It

Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis
Bowyer, Kasey , Liang, Jonathan , Swisher, Austin R , Jiang, Nancy

Mayo Clinic

Diseases of the Esophagus | July 1, 2025 | Volume: 38 | Issue: 4 | Pages: No page available

10.1093/dote/doaf055 | PMID 40662440 Get It

Summary Dupilumab, the first biologic approved for eosinophilic esophagitis treatment (EoE-tx) in 2022, demonstrated favorable safety in phase-III clinical trials. However, real-world dupilumab-associated adverse reactions (DARs) for EoE-tx are unknown. This study aims to evaluate DAR for EoE-tx using the FDA Adverse Event Reporting System. FDA Adverse Event Reporting System was queried for DAR between 2022Q1 and 2023Q4. Individual DARs (iDARs) were categorized and compared between treatment groups: EoE, asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Logistic regression was used to predict serious DAR and outcomes, and zero-truncated negative binomial regression was used to predict the number of iDAR. There were 51,000 DAR observations; 1459 for EoE-tx with 103 (7.1%) serious reactions and 44 (3.0%) serious outcomes including 3 deaths. For EoE-tx, the mean iDAR was 3.68 [3.51, 3.85], and the iDAR incidence rate ratio among men receiving EoE-tx was 0.73 [0.65, 0.83]. EoE-tx average iDAR primarily included general (0.75 [0.70, 0.80]), injection-site (0.69 [0.63, 0.74]), dermatologic (0.51 [0.46, 0.55]), and gastrointestinal (0.24 [0.21, 0.27]) reactions. Adults ≥50 years had 1.97 [1.28, 2.99] higher odds for serious DAR compared to younger adults in EoE-tx. Overall, dupilumab demonstrated a favorable safety profile across all indications, with low rates of serious adverse events. For EoE-tx specifically, higher total iDAR rates were observed, driven largely by increased injection-site and gastrointestinal reactions compared to other indications. Additionally, women exhibited higher iDAR rates than men across all indications.
Transgender and gender diverse patients’ preference and comfort for having a medical chaperone present during a sensitive physical examination: a single-site study
Linder, Katie E, Ramirez, Johanna L., Pankey, Tyson, Heredia, Dagoberto , Chang, Alice Y. , Davidge‐Pitts, Caroline , Imhof, Nicole, González, César A. , Linder, K , Imhof, Nicole R, Gonzalez, Cesar , Linder, Katharine E

Mayo Clinic

The Journal of Sexual Medicine | June 29, 2025 | Volume: 22 | Issue: 8 | Pages: 1504-1513

10.1093/jsxmed/qdaf147 | PMID 40581941 Get It

Abstract Background Medical chaperones are authorized individuals present during physical examinations involving the genitals, breasts/chest, or anal areas. The use of medical chaperones may provide an opportunity to improve transgender and gender diverse (TGD) patients’ experiences with sensitive examinations. Aim To examine TGD adult patients’ preferences and comfort for having a medical chaperone and whether TGD-specific characteristics, social anxiety symptoms, and feelings of medical mistrust are associated with preference for having a medical chaperone present during a sensitive physical examination. Methods This study used a cross-sectional survey that randomly sampled adult patients from a gender clinic in the Midwest region of the U.S. A total of 420 surveys were mailed. Sixty-two surveys were returned undeliverable, 358 reached recipients; 151 were returned (42.1% response rate). The survey included items related to demographics, gender-related anatomical dysphoria, social anxiety symptoms, feelings of medical mistrust, and preference and comfort towards medical chaperones. Results Among 149 respondents, 74 (49.7%) reported comfort for the idea of having a medical chaperone present during a sensitive physical examination, 50 (33.6%) reported neutral comfort, and 25 (16.8%) reported discomfort. Among 147 respondents, 89 (60.5%) endorsed a preference for a female medical chaperone. We found no associations between gender-related anatomical dysphoria or social anxiety symptoms and comfort for having a medical chaperone, or the gender preference for a medical chaperone. Medical mistrust was associated with lower comfort with having a medical chaperone present during a sensitive physical examination. Clinical Implications Routinely offering medical chaperones, especially female chaperones, is like to be generally acceptable to most TGD patients. These findings may inform clinic policies on providing medical chaperones during sensitive examinations. Strengths and Limitations This study is the first to examine TGD preferences for medical chaperones. Findings are limited by a single site, homogeneous sample, cross-sectional design, and reliance on hypothetical rather than observed examinations. Conclusion TGD adults report comfort with the concept of having a medical chaperone during sensitive examinations and most would prefer the chaperone to be female. Preference for having a medical chaperone present during a sensitive physical exam is not likely influenced by gender dysphoria or social anxiety.
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer
Moyer, Jacob A. , Durant, Adri , Nguyen, Mimi V., Mi, Lanyu , Zganjar, Andrew , Shah, Paras , Boorjian, Stephen A. , Tyson, Mark D. , Zganjar, Andrew J., Lyon, Timothy D.

Mayo Clinic

Journal of Urology | June 26, 2025 | Volume: 214 | Issue: 4 | Pages: 393-399

10.1097/ju.0000000000004658 | PMID 40569326 Get It

Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
Haupt, Eric C. , Chawla, Neetu , Osuji, Thearis A. , Shen, Ernest , Casperson, Mallory, Kirchhoff, Anne C. , Zebrack, Brad , Laurent, Cecile A. , Keegan, Theresa H.M. , Abrahão, Renata , Ruddy, Kathryn J. , Nichols, Hazel B. , Wernli, Karen J. , Hahn, Erin E , Haupt, Eric C , Chawla, Neetu , Kirchhoff, Anne C , Zebrack, Bradley J , Laurent, Cecile A , Keegan, Theresa H M , Abrahão, Renata , Ruddy, Kathryn J , Chubak, Jessica , Nichols, Hazel B , Wernli, Karen J , Smitherman, Andrew B. , Chubak, Jessica

Mayo Clinic

JCO Oncology Practice | June 20, 2025 | Volume: 22 | Issue: 5 | Pages: 780-792

10.1200/op-24-00886 | PMID 40540706 Get It

PURPOSE Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.
A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint
Vega, Rodolfo E. De la , Sellon, Jacob L. , Smith, Jay , Wisniewski, Stephen, Jurisson, Mary L. , Frick, Matthew A., Scrabeck, Tyson L., Block, Julie B., Mills, Candee J. , Pohlkamp, Zachary W., Coenen, Michael J., Hawse, Gresin P. , Abdul, Temilola Y. , Conaghan, Philip G. , Keravala, Annahita, Robbins, Paul D. , Ghivizzani, Steven C. , Evans, Christopher H. , De La Vega, Rodolfo E , Wisniewski, Stephen J, Conaghan, Philip , Chalberg, Thomas W , Robbins, Paul D , Ghivizzani, Steven C , Evans, Christopher H , Block, Julie B.

Mayo Clinic

Science Translational Medicine | June 4, 2025 | Volume: 17 | Issue: 801 | Pages: No page available

10.1126/scitranslmed.adu9804 | PMID 40465688 Get It

Osteoarthritis (OA) is a major global health problem with no disease-modifying therapies. Interleukin-1 (IL-1) is a critical cytokine associated with the pathophysiology of OA and can be inhibited by IL-1 receptor antagonist (IL-1Ra). Here, we tested the delivery of a gene therapeutic encoding the human IL-1Ra to the knee in a phase 1, open-label clinical trial that enrolled nine patients with radiographic knee OA. The IL-1Ra gene was delivered by a self-complementary (sc)–recombinant adeno-associated virus (rAAV) serotype 2.5 (sc-rAAV2.5IL-1Ra) by intra-articular injection into an index knee at one of three doses: low [1 × 10 11 viral genomes (vg)], mid (1 × 10 12 vg), or high (1 × 10 13 vg). The primary outcome was safety. There were no serious adverse events (AEs) related to sc-rAAV2.5IL-1Ra. Two AEs occurred that were possibly related to the vector. Both were effusions with increased pain and resolved with conservative treatment. sc-rAAV2.5IL-1Ra did not cause changes in vital signs, physical findings, or clinical laboratory measures. Less than 1% of the injected dose of sc-rAAV2.5IL-1Ra vg was detected in circulation after 1 day and was cleared within a week. Titers of neutralizing antibodies to AAV2.5 rose in serum and synovial fluid. In all cases, IL-1Ra concentration increased in the synovial fluid, and IL-1Ra concentrations remained elevated after 1 year. Baseline pain and function scores improved during the study. Therefore, we found that intra-articular gene therapy with sc-rAAV2.5IL-1Ra was safe. The sustained increase in local IL-1Ra in human knee joints supports the further clinical examination of this therapy to provide therapeutic benefit in OA.
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Tyson, Mark D. , Agarwal, Gautum, Goldfischer, Evan R., Williams, Michael B. , Baayen, Corine , Sandström, Per , Shore, Neal D. , Juul, Kristian Vinter , Sandstrom, Per, Narayan, Vikram M.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps4632 Get It

TPS4632 Background: There is currently no Food and Drug Administration (FDA)-approved treatment for intermediate-risk non–muscle-invasive bladder cancer (IR NMIBC), defined as recurrence of low-grade (LG) Ta within 1 year, solitary LG Ta > 3 cm, multifocal LG Ta, high-grade (HG) Ta (≤3 cm), and/or LG T1. Nadofaragene firadenovec-vncg is the first FDA-approved intravesical nonreplicating gene therapy for treating high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) ± papillary tumors. In a nonrandomized, multicenter, open-label, repeat-dose, phase 3 study, 53.4% of participants (55/103) with CIS ± HG Ta/T1 achieved complete response 3 months after the first instillation. Nadofaragene firadenovec was well tolerated, with no grade 4/5 study drug-related AEs. Because maintenance treatment with nadofaragene firadenovec following tumor resection may improve clinical outcomes in patients with IR NMIBC, the ABLE-32 open-label randomized study is being conducted to evaluate the efficacy of nadofaragene firadenovec administered every 3 months versus observation in participants with IR NMIBC. Methods: This phase 3 study includes approximately 100 global sites with 454 anticipated participants. Adults aged ≥18 years, diagnosed with new or recurrent IR NMIBC, and having undergone transurethral resection of bladder tumor within 60 days prior to randomization are eligible. Participants will be randomly assigned 1:1 to receive nadofaragene firadenovec or continue observation. The nadofaragene firadenovec group will receive quarterly doses unless disease recurs or progresses. The observation group will be followed quarterly and may receive nadofaragene firadenovec if IR NMIBC recurs within 24 months. All participants will be evaluated for recurrence and progression using cytology, cystoscopy, and for-cause biopsy for up to 5 years. The primary endpoint is recurrence-free survival (RFS), from randomization to first documented recurrence, progression, or death. Secondary endpoints include RFS at 12 and 24 months and safety. Exploratory endpoints include effect on potential biomarkers and health-related quality of life. Final results are expected in 2031. Clinical trial information: NCT06510374 .
Economic Impact Model of Incorporating Cxbladder Monitor in the Surveillance of Nonmuscle Invasive Bladder Cancer
Tyson, Mark D. , Sfakianos, John P. , Shoskes, Daniel A., Muench, Tobias, Seemann, K. , Saunders, Rhodri , Daneshmand, Siamak

Mayo Clinic

JU Open Plus | April 7, 2025 | Volume: 3 | Issue: 4 | Pages: No page available

10.1097/ju9.0000000000000271 Get It

Introduction: Guideline recommended surveillance of nonmuscle invasive bladder cancer (NMIBC) involves frequent cystoscopies. Cxbladder Monitor (CxbM) is a noninvasive urinary genomic test with high negative predictive value for NMIBC recurrence. Incorporation of CxbM into surveillance could reduce the frequency, burden, and cost of surveillance. We studied this impact using a theoretical health economic model. Materials and Methods: A Markov model for disease dynamics and decision tree model for surveillance pathways were created for 100 patients with theoretical NMIBC risk stratified by AUA criteria over 5 years from diagnosis. In the standard of care (SOC) arm, cystoscopy was performed per AUA guidelines. In the CxbM surveillance arm, CxbM was used starting 9 months after diagnosis. If positive, cystoscopy was performed per guidelines, but if negative, the cystoscopy was not performed and on the next scheduled encounter. Primary outcome was total budgetary impact. Additional outcomes included number of diagnostic tests, test-related complications, and patients with delayed diagnosis. Results: Compared with SOC, CxbM reduced mean total costs by $68,621 for 100 patients over 5 years or $137.24 per patient per year. Cystoscopy was reduced by 129 (0.31 per patient per year), and there was no difference in delayed cancer diagnosis. Using a probabilistic model, the median cost reduction per patient per year was $160 (95% credible interval −520 to 109) with 86.2% probability of cost savings. Conclusions: In this Markov model, incorporation of CxbM into surveillance for NMIBC reduced cystoscopy without negative impact on cancer detection with cost savings for the majority of simulations run.